Replimune Group (REPL) Competitors

Travere Therapeutics (NASDAQ:TVTX) and Replimune Group (NASDAQ:REPL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Do institutionals & insiders have more ownership in TVTX or REPL?

92.5% of Replimune Group shares are owned by institutional investors. 4.2% of Travere Therapeutics shares are owned by insiders. Comparatively, 5.2% of Replimune Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Does the media prefer TVTX or REPL?

In the previous week, Replimune Group had 25 more articles in the media than Travere Therapeutics. MarketBeat recorded 39 mentions for Replimune Group and 14 mentions for Travere Therapeutics. Travere Therapeutics' average media sentiment score of 1.03 beat Replimune Group's score of -0.05 indicating that Travere Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Travere Therapeutics	5 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Replimune Group	1 Very Positive mention(s)	4 Positive mention(s)	28 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do analysts recommend TVTX or REPL?

Travere Therapeutics currently has a consensus price target of $32.21, suggesting a potential upside of 75.75%. Replimune Group has a consensus price target of $7.67, suggesting a potential upside of 36.54%. Given Travere Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Travere Therapeutics is more favorable than Replimune Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Travere Therapeutics	0 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.87
Replimune Group	1 Sell rating(s)	7 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.33

Which has stronger earnings & valuation, TVTX or REPL?

Replimune Group has lower revenue, but higher earnings than Travere Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Travere Therapeutics	$233.18M	7.01	-$321.55M	-$2.04	-8.99
Replimune Group	N/A	N/A	-$247.30M	-$3.24	-1.73

Is TVTX or REPL more profitable?

Replimune Group has a net margin of 0.00% compared to Travere Therapeutics' net margin of -50.64%. Replimune Group's return on equity of -69.34% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Travere Therapeutics	-50.64%	-717.68%	-30.69%
Replimune Group	N/A	-69.34%	-52.81%

Which has more volatility and risk, TVTX or REPL?

Travere Therapeutics has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500. Comparatively, Replimune Group has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500.

Summary

Travere Therapeutics and Replimune Group tied by winning 8 of the 16 factors compared between the two stocks.